Pharmaceutical

Daré Bioscience Inks Deal With Bayer for Non-Hormonal Contraceptive

5 days ago   |   By Xconomy

Daré Bioscience launched in 2015 with the aim of assembling a portfolio of novel women's health products intended to pique interest from major pharmaceutical companies. Now the San Diego-based company has inked its first deal with Big Pharma, signing an agreement with German biopharma Bayer for its lead asset, a monthly non-hormonal form of birth control. Under terms announced Monday, Bayer will pay Daré an undisclosed upfront sum to secure the right to license its experimental contraceptive, Ovaprene, for US commercialization. Daré this year plans to conduct a pivotal trial of Ovaprene...
Read more ...

 


Search by Tags

   Pharmaceutical      BioPharma      Biosciences      Biopharma      Health      Pharma      Pharmaceuticals      Europe blog main      National blog main      San Diego      San Diego blog main      San Diego top stories      Bayer      Biotech      Clinical trials      Deals      Dewpoint Therapeutics      Evofem      Licensing      Life Sciences      Startups  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Revolution Medicines Maps Out an IPO to Reach Cancer's Frontiers

Revolution Medicines Maps Out an IPO to Reach Cancer's Frontiers

Cancer research has revealed proteins known to play a role in the disease, but with no known way of stopping what they do. In pharmaceutical parlance, they're “undruggable.”... Read more ...

AveXis Inc.: Research Associate III

AveXis Inc.: OverviewReady to join a team committed to developing and commercializing gene therapies for patients and families devastated by rare neurological gene San Diego... Read more ...

Mirati Therapeutics: Student Assistant

Mirati Therapeutics: Mirati Therapeutics is a targeted oncology company developing an advanced pipeline of breakthrough medicines for precisely defined patient populations San... Read more ...

Inhibition of lignification of Zizania latifolia with radio frequency...

Zizania latifolia is easily lignified after harvesting, leading to the degradation of food quality and commercial value. Thus, this study evaluated the effect of radio... Read more ...

Performance difference of graph-based and alignment-based hybrid error...

The error-prone third-generation sequencing long reads can be corrected by the high-quality second-generation sequencing short reads, which is referred to as hybrid error... Read more ...

CHROMATIX: computing the functional landscape of many-body chromatin...

Chromatin interactions are important for gene regulation and cellular specialization. Emerging evidence suggests many-body spatial interactions play important roles in... Read more ...

Bachem: Validation Engineer II, QA

Bachem: Your Responsibilities The Validation Engineer II fulfills a critical role in GMP operations. This individual must plan and execute validation studies, Vista, CA, US ... Read more ...

AveXis Inc.: Senior Scientist, Molecular Biology

AveXis Inc.: OverviewReady to join a team committed to developing and commercializing gene therapies for patients and families devastated by rare neurological gene San Diego... Read more ...

Mirati Therapeutics: Talent Partner

Mirati Therapeutics: Reporting to the Head of Business, Culture and Talent this role will be partner with C-Level executive(s) and their staff. This role will be responsib San... Read more ...

Selective inhibition of matrix metalloproteinase 10 with a single-domain...

Since their discovery, the matrix metalloproteinase family of proteases have been considered as therapeutic targets in numerous diseases and disorders. Unfortunately, clinical... Read more ...